HK1079989A1 - Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response - Google Patents

Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Info

Publication number
HK1079989A1
HK1079989A1 HK06100064.5A HK06100064A HK1079989A1 HK 1079989 A1 HK1079989 A1 HK 1079989A1 HK 06100064 A HK06100064 A HK 06100064A HK 1079989 A1 HK1079989 A1 HK 1079989A1
Authority
HK
Hong Kong
Prior art keywords
cells
compositions
response
methods
monocytic dendritic
Prior art date
Application number
HK06100064.5A
Other languages
English (en)
Inventor
Marnix L Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of HK1079989A1 publication Critical patent/HK1079989A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
HK06100064.5A 2001-09-06 2006-01-04 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response HK1079989A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31759201P 2001-09-06 2001-09-06
PCT/US2002/028620 WO2003022215A2 (en) 2001-09-06 2002-09-06 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Publications (1)

Publication Number Publication Date
HK1079989A1 true HK1079989A1 (en) 2006-04-21

Family

ID=32654226

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100064.5A HK1079989A1 (en) 2001-09-06 2006-01-04 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Country Status (18)

Country Link
US (2) US20050059151A1 (pt)
EP (3) EP3653055A1 (pt)
JP (3) JP2005505270A (pt)
KR (3) KR20050027163A (pt)
CN (2) CN102973928B (pt)
AU (1) AU2008221592B2 (pt)
BR (1) BRPI0212545B8 (pt)
CA (1) CA2459713C (pt)
DK (2) DK1441591T3 (pt)
ES (2) ES2598109T3 (pt)
HK (1) HK1079989A1 (pt)
IL (3) IL160720A0 (pt)
MX (1) MXPA04002147A (pt)
NO (2) NO338147B1 (pt)
NZ (1) NZ531530A (pt)
PL (1) PL372098A1 (pt)
PT (2) PT2322603T (pt)
WO (1) WO2003022215A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
ES2354944T3 (es) * 2002-12-06 2011-03-21 Northwest Biotherapeutics, Inc. Administración de células dendríticas maduradas parcialmente in vitro para el tratamiento de tumores.
AU2004214896A1 (en) * 2003-02-27 2004-09-10 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
JP2007507543A (ja) * 2003-10-06 2007-03-29 セダーズ−シナイ メディカル センター 樹状細胞治療によって誘導されるｔ細胞アネルギーを予防するためのｃｏｘ−２インヒビターの使用
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
CN1902312B (zh) * 2003-11-04 2011-02-23 株式会社载体研究所 制备导入了基因的树突细胞的方法
WO2006001120A1 (ja) 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
KR20180049169A (ko) * 2005-12-08 2018-05-10 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
US8129184B2 (en) * 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
DK2328923T3 (en) * 2008-09-02 2016-03-21 Cedars Sinai Medical Center CD133 epitopes
WO2010129895A2 (en) 2009-05-07 2010-11-11 Immunocellular Therapeutics, Ltd. Cd133 epitopes
SG11201404543UA (en) * 2012-02-02 2014-08-28 California Stem Cell Inc Pluripotent germ layer origin antigen presenting cancer vaccine
KR101704745B1 (ko) 2012-05-31 2017-02-08 제이더블유크레아젠 주식회사 수지상세포 성숙화 조성물 및 이를 이용하여 항원 특이적 수지상세포를 제조하는 방법
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
CA2891602C (en) 2012-12-12 2017-10-24 Orbis Health Solutions, Llc Composition comprising an orthosilicate and its use for tissue regeneration
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
CN104936612B (zh) * 2013-09-05 2021-01-01 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
KR102060858B1 (ko) 2014-03-05 2019-12-30 오르비스 헬스 솔루션즈 엘엘씨 효모 세포벽 입자를 사용하는 백신 전달 시스템
US9972054B1 (en) 2014-05-20 2018-05-15 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US10089693B1 (en) 2014-05-20 2018-10-02 State Farm Mutual Automobile Insurance Company Fully autonomous vehicle insurance pricing
US10599155B1 (en) 2014-05-20 2020-03-24 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10373259B1 (en) 2014-05-20 2019-08-06 State Farm Mutual Automobile Insurance Company Fully autonomous vehicle insurance pricing
US11669090B2 (en) 2014-05-20 2023-06-06 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10540723B1 (en) 2014-07-21 2020-01-21 State Farm Mutual Automobile Insurance Company Methods of providing insurance savings based upon telematics and usage-based insurance
US10241509B1 (en) 2014-11-13 2019-03-26 State Farm Mutual Automobile Insurance Company Autonomous vehicle control assessment and selection
IL256522B1 (en) * 2015-06-30 2024-06-01 Northwest Biotherapeutics Inc Optimally activated dendritic cells that result in an enhanced or enhanced antitumor immune response
WO2017002045A1 (en) 2015-06-30 2017-01-05 Stemlab, Sa A viable cell population, method for production and uses thereof
US20210166323A1 (en) 2015-08-28 2021-06-03 State Farm Mutual Automobile Insurance Company Determination of driver or vehicle discounts and risk profiles based upon vehicular travel environment
US11441916B1 (en) 2016-01-22 2022-09-13 State Farm Mutual Automobile Insurance Company Autonomous vehicle trip routing
US10134278B1 (en) 2016-01-22 2018-11-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle application
US10324463B1 (en) 2016-01-22 2019-06-18 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation adjustment based upon route
US10295363B1 (en) 2016-01-22 2019-05-21 State Farm Mutual Automobile Insurance Company Autonomous operation suitability assessment and mapping
US11242051B1 (en) 2016-01-22 2022-02-08 State Farm Mutual Automobile Insurance Company Autonomous vehicle action communications
US11719545B2 (en) 2016-01-22 2023-08-08 Hyundai Motor Company Autonomous vehicle component damage and salvage assessment
US10395332B1 (en) 2016-01-22 2019-08-27 State Farm Mutual Automobile Insurance Company Coordinated autonomous vehicle automatic area scanning
KR102038114B1 (ko) * 2016-02-26 2019-10-30 주식회사 엘지화학 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
KR20220098351A (ko) * 2019-10-07 2022-07-12 노쓰웨스트 바이오써라퓨틱스, 인크. 수지상 세포 및 T 세포의 활성화를 증진시키고 Th-1 면역 반응을 유도하기 위한 시험관내 방법 및 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
DE69637942D1 (de) * 1995-10-04 2009-07-09 Immunex Corp Stimulationsfaktor für dendriten
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US6274378B1 (en) * 1997-10-27 2001-08-14 The Rockefeller University Methods and compositions for obtaining mature dendritic cells
JP2000143534A (ja) * 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
JP2000279181A (ja) * 1999-04-01 2000-10-10 Japan Science & Technology Corp ヒト樹状細胞の発現遺伝子群
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
US6247378B1 (en) * 2000-01-06 2001-06-19 Deere & Company Operator control device for an infinitely variable transmission
IL152655A0 (en) * 2000-05-12 2003-06-24 Northwest Biotherapeutics Inc Method to increase class i presentation of exogenous antigens by human dendritic cells
EP1352052B1 (en) * 2001-01-15 2006-02-08 I.D.M. Immuno-Designed Molecules Method for preparing submicron particle suspensions of pharmaceutical agents
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors

Also Published As

Publication number Publication date
JP2015107133A (ja) 2015-06-11
KR20110081341A (ko) 2011-07-13
IL219266A0 (en) 2012-06-28
IL160720A (en) 2012-05-31
WO2003022215A3 (en) 2003-11-13
CN1636229A (zh) 2005-07-06
EP1441591B1 (en) 2016-06-29
EP1441591A4 (en) 2006-06-07
NZ531530A (en) 2007-01-26
JP6114768B2 (ja) 2017-04-12
DK2322603T3 (da) 2020-01-27
BRPI0212545B8 (pt) 2021-05-25
IL219266A (en) 2014-02-27
NO338147B1 (no) 2016-08-01
CN102973928B (zh) 2019-03-15
PL372098A1 (en) 2005-07-11
EP1441591A2 (en) 2004-08-04
EP2322603B1 (en) 2019-10-16
KR20140116544A (ko) 2014-10-02
DK1441591T3 (en) 2017-05-22
PT2322603T (pt) 2020-01-21
BR0212545A (pt) 2005-01-18
CN1636229B (zh) 2012-12-19
IL160720A0 (en) 2004-08-31
KR20050027163A (ko) 2005-03-17
BRPI0212545A8 (pt) 2019-10-15
WO2003022215A2 (en) 2003-03-20
CN102973928A (zh) 2013-03-20
AU2008221592B2 (en) 2012-12-20
MXPA04002147A (es) 2005-03-07
BRPI0212545B1 (pt) 2019-12-03
US20050059151A1 (en) 2005-03-17
NO20151562A1 (no) 2015-11-16
NO20040965L (no) 2004-04-23
ES2598109T3 (es) 2017-01-25
EP3653055A1 (en) 2020-05-20
CA2459713A1 (en) 2003-03-20
PT1441591T (pt) 2016-10-06
CA2459713C (en) 2015-08-18
AU2008221592A1 (en) 2008-10-16
KR101803702B1 (ko) 2017-12-01
EP2322603A1 (en) 2011-05-18
JP2005505270A (ja) 2005-02-24
JP2011188872A (ja) 2011-09-29
US20080254064A1 (en) 2008-10-16
JP5777956B2 (ja) 2015-09-16
ES2766299T3 (es) 2020-06-12

Similar Documents

Publication Publication Date Title
IL219266A0 (en) Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
AU2003253897A8 (en) Dendritic cell pontentiation
AU2002318944A1 (en) Methods and compositions relating to plasmacytoid dendritic cells
AU2002360480A1 (en) Ultrastable porous aluminosilicates strucures and compositions derived therefrom
IL159578A (en) Differentiated cell population for generating osteoprogenitors or osteoblasts
EP1551372B8 (en) Sequestering subunit and related compositions and methods
AU2002249531A1 (en) Immunotherapy based on dendritic cells
AU2008243079A1 (en) Compositions and methods for generating an immune response
AU2002367825A8 (en) Graft polymer matrices
EP1447092A4 (en) METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
AU2001283240A1 (en) High expansion dental alloys
AU2003297595A8 (en) Atm kinase compositions and methods
GB0319495D0 (en) An implant
AU2003247449A1 (en) Nano-ceramics and method thereof
AU2002305452A1 (en) Regulating immine responses using dendritic cells
AU2002228932A1 (en) Maturation of dendritic cells
GB0217907D0 (en) Polymerisable dicyclohexylbenzenes
AU2002365938A8 (en) Modified antigen-presenting cells
AU2003278407A1 (en) Sustained release compositions containing alfuzosin
EP1411897A4 (en) COMPOSITIONS AND METHODS FOR INTRA-CELLULAR DELIVERY
AU2003214985A1 (en) Polymerized wax candles
AU2001283226A1 (en) Methods and compositions for inhibiting rad51
EP1283727A4 (en) COMPOSITIONS AND METHODS FOR INDUCING THE ACTIVATION OF DENDRITIC CELLS
AU2002365136A8 (en) Compositions and methods for controlled release
AU2002336522A1 (en) Compositions and methods for t cell priming and immunotherapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210910